Over 73% of Americans over the age of 20 are obese or overweight, according to the Centers for Disease Control and Prevention (CDC)

- UCHealth, accessed April 22, 2025, What is the MOA for GLP-1 drugs and how do they work?, accessed April 22, 2025, Transform Your Health: The Power of GLP-1 Injections for Effective Weight Loss, accessed April 22, 2025, Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf, accessed April 22, 2025, Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS in, accessed April 22, 2025, How GLP-1 Medications Affect Appetite | Big Tree Medical Weight Loss, accessed April 22, 2025, Effects of GLP-1 on appetite and weight - PMC - PubMed Central, accessed April 22, 2025, 19 Semaglutide (Ozempic, Wegovy) Side Effects You Should Know About - GoodRx, accessed April 22, 2025, Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists - PubMed, accessed April 22, 2025, Should glucagon-like peptide 1 receptor agonists be withheld during the preoperative period

GLP-1 therapies are poised for continued growth, with 24% of consumers currently considering GLP-1s and 65% of providers willing to prescribe them
As of December 31, 2019, the Company had 142,150,096 shares of $0.0001 par value convertible preferred stock, or Convertible Preferred Stock, authorized, of which 2,280,000 shares are designated as Series A convertible preferred stock, or Series A Preferred